Bio Blast Pharma Ltd (ORPN) Releases Earnings Results, Beats Expectations By $0.05 EPS

Bio Blast Pharma Ltd (ORPN) reported quarterly earnings results on Thursday, Aug-25-2016. The company said it had a profit of $-0.22 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $-0.27. During the same quarter in the previous year, the company posted $-0.26 EPS.

Bio Blast Pharma Ltd opened for trading at $1.9 and hit $1.97 on the upside on Tuesday, eventually ending the session at $1.88, with a gain of 0.53% or 0.01 points. The heightened volatility saw the trading volume jump to 1,04,998 shares. Company has a market cap of $27 M.

Bio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification licensing acquisition development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The Company is advancing its Cabaletta platform product candidates through clinical development and advancing its other product candidates BB-FA BB-OTC and BBrm1 as well as its other early stage research projects through preclinical development. The Company’s three principal product candidate platforms include Protein Stabilizing Platform Read-through Platform and Mitochondrial Protein Replacement Platform. The Company is developing Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD); spinocerebellar ataxia type 3 (SCA3) and Spinobulbar Muscular Atrophy (SBMA). It is conducting preclinical studies of BBrm1 for the treatment of Spinal Muscular Atrophy (SMA).

Bio Blast Pharma Ltd

Leave a Reply

Bio Blast Pharma Ltd - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bio Blast Pharma Ltd. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.